Omeros Corporation Cash Flow Conversion Efficiency
Omeros Corporation cash flow conversion efficiency. Based on the latest financial reports, Omeros Corporation (OMER) has a cash flow conversion efficiency ratio of -0.081x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.15 Million) by net assets ($-51.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Omeros Corporation (2007–2025)
Cash flow conversion efficiency of Omeros Corporation from 2007 to 2025. This chart illustrates how Omeros Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Omeros Corporation (OMER) share price today for real-time trading data and today's change.
Omeros Corporation Cash Flow Conversion Ratio Explained
Omeros Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Omeros Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omeros Corporation ranked by their cash flow conversion efficiency. Also see Omeros Corporation stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dole PLC
NYSE:DOLE
|
-0.015x |
|
Ocean’s King Lighting Science & Technology Co Ltd
SHE:002724
|
-0.003x |
|
WEBTOON Entertainment Inc. Common stock
NASDAQ:WBTN
|
-0.005x |
|
Trident Limited
NSE:TRIDENT
|
0.140x |
|
Ennostar Inc
TW:3714
|
0.016x |
|
Eaglerise Electric & Electronic China Co Ltd Class A
SHE:002922
|
0.038x |
|
Xiamen Meiya Pico Information
SHE:300188
|
-0.013x |
|
Manorama Industries Limited
NSE:MANORAMA
|
0.299x |
Annual Cash Flow Conversion Efficiency for Omeros Corporation (2007–2025)
The table below shows the annual cash flow conversion efficiency of Omeros Corporation from 2007 to 2025. Review Omeros Corporation free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-121.23 Million | $-116.09 Million | 0.958x | +17.52% |
| 2024-12-31 | $-182.61 Million | $-148.80 Million | 0.815x | +127.24% |
| 2023-12-31 | $-24.98 Million | $74.73 Million | -2.991x | -196.34% |
| 2022-12-31 | $85.68 Million | $-86.48 Million | -1.009x | +78.12% |
| 2021-12-31 | $23.78 Million | $-109.72 Million | -4.614x | -656.68% |
| 2020-12-31 | $-120.75 Million | $-100.09 Million | 0.829x | +50.42% |
| 2019-12-31 | $-109.02 Million | $-60.07 Million | 0.551x | +153.20% |
| 2018-12-31 | $100.16 Million | $-103.74 Million | -1.036x | -108.05% |
| 2017-12-31 | $-2.81 Million | $-36.23 Million | 12.874x | +836.02% |
| 2016-12-31 | $-37.45 Million | $-51.50 Million | 1.375x | -44.67% |
| 2015-12-31 | $-26.23 Million | $-65.21 Million | 2.486x | +82.66% |
| 2014-12-31 | $-42.65 Million | $-58.04 Million | 1.361x | -15.75% |
| 2013-12-31 | $-18.38 Million | $-29.70 Million | 1.615x | +903.15% |
| 2012-12-31 | $-214.58 Million | $-34.55 Million | 0.161x | -96.52% |
| 2011-12-31 | $-5.55 Million | $-25.67 Million | 4.622x | +752.34% |
| 2010-12-31 | $20.47 Million | $-14.50 Million | -0.708x | -60.65% |
| 2009-12-31 | $43.15 Million | $-19.03 Million | -0.441x | -304.36% |
| 2008-12-31 | $-91.17 Million | $-19.67 Million | 0.216x | +5.44% |
| 2007-12-31 | $-69.94 Million | $-14.31 Million | 0.205x | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more